GlassScriptPhysician profile
John Chukwudifu
NPI 1033628235
$4,639.62
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $1,655 · 2023: $1,625 · 2024: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.22 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.94 | 2021-2024 | |
| Celgene Corporation | $1,072.65 | 2021-2024 | Zeposia |
| Lundbeck LLC | $554.48 | 2022-2024 | Vyepti |
| Emd Serono, INC. | $386.86 | 2022-2024 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $322.01 | 2021-2024 | Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $181.64 | 2022 | |
| Sk Life Science, INC. | $100.41 | 2023-2024 | Xcopri |
| E.R. Squibb & Sons, L.L.C. | $91.58 | 2024 | Zeposia |
| Pfizer INC. | $80.45 | 2023-2024 | |
| Lilly USA, LLC | $75.52 | 2021-2023 | Emgality |
| Novartis Pharmaceuticals Corporation | $74.43 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $67.04 | 2021 | |
| Biogen, INC. | $61.70 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Otsuka America Pharmaceutical, INC. | $41.57 | 2024 | Nuedexta |
| Genzyme Corporation | $37.11 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $29.16 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $24.74 | 2023 | Rytary |
| Avion Pharmaceuticals | $24.06 | 2022 | |
| Allergan, INC. | $23.87 | 2022 | |
| Genentech USA, INC. | $19.49 | 2023 | Enspryng, Ocrevus |
| Csl Behring | $18.20 | 2021 | |
| Acadia Pharmaceuticals INC | $17.97 | 2022 | |
| Amgen INC. | $17.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chukwudifu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.